Analysis of dynamics of the medcine list in the government program «available medicines» for treatment of bronchial asthma

Keywords: reimbursation, a range of medicines, bronchial asthma

Abstract

The problem of accessibility for socially significant goods for the population, among which the most important place occupy medicines in Ukraine, is very acute today. In this regard, the need for specific state interference through regulatory processes becomes relevant. One of the priority directions for increasing the availability of medicines is the Government of Ukraine has recognized reimbursement.

The mechanism of full or partial payment of the cost of medicines used to counteract most socially significant diseases. One of these diseases is bronchial asthma (BA), since it affects all age groups of the population, and with ineffective control of the disease, the quality of life of patients is significantly reduced.

The aim of the work is to study the range of medicines for the treatment of BA, included in the Government program «Accessible medicines» for the period 2017–2019 years.

From April 1, 2017 to July 1, 2019, the Ministry of Health of Ukraine issued five orders, which approved the Register of medicines, the cost of which is subject to reimbursement. In the study analyzed all editions of the Register and found that with each update, the number of trade names (TN) of the medicines increased: for the treatment of cardiovascular diseases – by 56%, diabetes – by 92%, and BA – by 133%. During the 2017–2019 years, the number of international non-proprietary names (INNs) for the treatment of BA also increased: 3 times Beclomethasone, Budesonide 3.5 times, and Salbutamol is almost 2 times. Also, found that 87% of TN are imported and only 13% – domestic. Total of medicines for the treatment of asthma, the value of which is refundable imports 6 countries, the main segment of which is formed by Spain (31%) and Sweden (23%). The analysis of the size and amount of rejection and the amount of the surcharge for packaging allows us to establish that the percentage of medicines without an additional payment is approximately up to 50%. At 75% of the medicines for the treatment of BA, the amount of packing surcharge with each edition of the Register of medicines subject to reimbursement was increased by 2 medicines (Beckhazon-eco 100 mcg/dose and 250 mcg/dose) and 1 medicine (Budesonide-inteli 200 mcg/dose) – decreased 1 medicine (Budesonide-inteli 200 mcg/dose) subject to partial compensation only once.

The conducted studies allow us to conclude that there is a need to improve the assortment policy in order to provide the pharmaceutical market with the available and necessary domestic medicines, in accordance with the needs of the population and the standards for the treatment of BA.

References

1. Medicines Reimbursement policies in Europe. World Health Organization 2018. – 182 р. // World Health Organization 2018 [Electronic resource]. – Mode of access: http://www.euro.who.int/__data/assets/pdf_file/0011/376625/pharmaceutical-reimbursement-eng.pdf?ua=1
2. Ofitsiyniy sayt Farmatsevtichnoyi entsiklopediyi [Elektronniy resurs]. – Rezhim dostupu: https://www.pharmencyclopedia.com.ua/article/1062/reimbursaciya
3. Ofitsiyniy sayt Tsentru gromadskogo zdorov’ya MOZ Ukrayini [Elektronniy resurs]. – Rezhim dostupu: https://phc.org.ua/news/bronkhialna-astma-scho-treba-znati-pro-zakhvoryuvannya
4. Ofitsiyniy sayt Uryadovoyi programi reimbursatsiyi «Dostupni liki» [Elektronniy resurs]. – Rezhim dostupu: http://liky.gov.ua/
5. Postanova Kabinetu Ministriv Ukrayini vid 9 listopada 2016 roku № 863 «Pro zaprovadzhennya vidshkoduvannya vartosti likarskih zasobiv» [Elektronniy resurs]. – Rezhim dostupu: https://zakon.rada.gov.ua/laws/show/863-2016-%D0%BF
6. Postanova Kabinetu Ministriv Ukrayini vid 27 lyutogo 2019 roku № 135 «Deyaki pitannya reimbursatsiyi likarskih zasobiv» [Elektronniy resurs]. – Rezhim dostupu: https://zakon.rada.gov.ua/laws/show/135-2019-%D0%BF
7. Getalo O. V., Kratenko A. O. Analiz sotsialno-ekonomichnogo stanu sistemi reimbursatsiyi vartosti likarskih zasobiv za kordonom // ΛΌГOΣ. The art of scientific mind. – 2019. – № 2. – S. 62–64.
8. Kosyachenko K. L., Nemchenko A. S., Kovalenko O. V., Kubareva I. V. Naukovo-metodichni pidhodi do provedennya monitoringu tsin na likarski zasobi, scho zakupovuyutsya za derzhavnimi tsilovimi programami // Farmats. zh. – 2011. – № 1. – S. 13–18.
9. Guz V. S., Zaliska O. M. Analiz dinamiki asortimentu likarskih zasobiv u programi «Dostupni liki» dlya likuvannya sertsevo-sudinnih zahvoryuvan // Farmats. zh. – 2019. – № 3. – S. 21–30. https://doi.org/10.32352/0367-3057.3.19.03
10. Nakaz MOZ Ukrayini vid 03. 04. 2017 r. № 360 «Pro zatverdzhennya Reestru likarskih zasobiv, vartist yakih pidlyagae vidshkoduvannyu» [Elektronniy resurs]. – Rezhim dostupu: https://zakon.rada.gov.ua/rada/show/v0360282-17
11. Nakaz MOZ Ukrayini vid 26. 07. 2017 r. № 856 «Pro zatverdzhennya Reestru likarskih zasobiv, vartist yakih pidlyagae vidshkoduvannyu stanom na 26 lipnya 2017 roku» [Elektronniy resurs]. – Rezhim dostupu: https://zakon.rada.gov.ua/rada/show/v0856282-17
12. Nakaz MOZ Ukrayini vid 22. 01. 2018 r. № 111 «Pro zatverdzhennya Reestru likarskih zasobiv, vartist yakih pidlyagae vidshkoduvannyu stanom na 22 sichnya 2018 roku» [Elektronniy resurs]. – Rezhim dostupu: https://zakon.rada.gov.ua/rada/show/v0111282-18
13. Nakaz MOZ Ukrayini vid 23. 07. 2018 r. № 1367 «Pro zatverdzhennya Reestru likarskih zasobiv, vartist yakih pidlyagae vidshkoduvannyu stanom na 23 lipnya 2018 roku» [Elektronniy resurs]. – Rezhim dostupu: https://zakon.rada.gov.ua/rada/show/v1367282-18
14. Nakaz MOZ Ukrayini vid 21. 01. 2019 r. № 148 «Pro zatverdzhennya Reestru likarskih zasobiv, vartist yakih pidlyagae vidshkoduvannyu stanom na 21 sichnya 2019 roku» [Elektronniy resurs]. – Rezhim dostupu: https://zakon.rada.gov.ua/rada/show/v0148282-19
Published
2019-10-29
How to Cite
Kostiuk, I. A. (2019). Analysis of dynamics of the medcine list in the government program «available medicines» for treatment of bronchial asthma. Farmatsevtychnyi Zhurnal, (5), 12-20. https://doi.org/10.32352/0367-3057.5.19.02
Section
Management of pharmacy